Scleroderma Diagnostics Therapeutics

Scleroderma Diagnostics and Therapeutics Market (Drug Class - Corticosteroids, Immunosuppressive Agents, Endothelin Receptor Agonists, Calcium Channel Blockers, PDE-5 Inhibitors, Chelating Agents, Prostacyclin Analogues, H2 Blockers, Proton Pump Inhibitors, and ACE Inhibitors; Indication - Localized and Systemic; Diagnostic Test Type - Skin Biopsy, Imaging Techniques, Blood Test, Electrocardiogram and Echocardiogram, and Pulmonary Function Tests) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2024

  • Rep Id : TMRGL2498
  • Published On : Apr 2018
  • No. of Pages : 176
  • Category : Pharmaceutical

Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

Chapter 2. Assumptions and Research Methodology

Chapter 3. Executive Summary: Global Scleroderma Diagnostics and Therapeutics Market

Chapter 4. Market Overview
4.1. Introduction
        4.1.1. Drug Class Definition
        4.1.2. Industry Developments
4.2. Market Dynamics
        4.2.1. Drivers
        4.2.2. Restraints
        4.2.3. Opportunity
4.3. Porters Five Forces Analysis
4.4. Global Scleroderma Diagnostics and Therapeutics Market Analysis and Forecasts, 2014–2024
4.5. Scleroderma Diagnostics and Therapeutics Market Outlook
4.6. Scleroderma : Overview of Clinical Trials

Chapter 5. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Indication 
5.1. Key Findings
5.2. Introduction
5.3. Market Size (US$ Mn) Forecast, by Indication
        5.3.1. Localized
        5.3.2. Systemic
5.4. Market Attractiveness Analysis, by Indication, 2015
5.5. Key Trends and Developments

Chapter 6. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market Size (US$ Mn) Forecast, by Drug Class
        6.3.1. Corticosteroids
        6.3.2. Immunosuppressive Agents
        6.3.3. Endothelin receptor antagonists 
        6.3.4. Calcium Channel Blockers
        6.3.5. PDE-5 Inhibitors
        6.3.6. Chelating Agents
        6.3.7. Prostacyclin analogues
        6.3.8. Others 
6.4. Market Attractiveness Analysis, by Drug Class, 2015
6.5. Key Trends and Developments

Chapter 7. Global Scleroderma Therapeutics Market Analysis and Forecasts, By Region
7.1. Key Findings
7.2. Introduction
7.3. Market Size (US$ Mn) Forecast, by Region
        7.3.1. North America
        7.3.2. Europe
        7.3.3. Asia Pacific
        7.3.4. Latin America
        7.3.5. Middle East & Africa
7.4. Market Attractiveness Analysis, by Region, 2015
7.5. Key Trends

Chapter 8. North America Scleroderma Therapeutics Market Analysis and Forecast
8.1. Key Findings
8.2. Introduction
8.3. Market Size (US$ Mn) Forecast, by Indication 
        8.3.1. Localized
        8.3.2. Systemic
8.4. Market Size (US$ Mn) Forecast, by Drug Class
        8.4.1. Corticosteroids
        8.4.2. Immunosuppressive Agents
        8.4.3. Endothelin receptor antagonists 
        8.4.4. Calcium Channel Blockers
        8.4.5. PDE-5 Inhibitors
        8.4.6. Chelating Agents
        8.4.7. Prostacyclin analogues
        8.4.8. Others 
8.5. Market Size (US$ Mn) Forecast, by Country
        8.5.1. U.S.
        8.5.2. Canada
8.6. Market Attractiveness Analysis, by Indication, 2015
8.7. Market Attractiveness Analysis, by Drug Class, 2015
8.8. Key Trends

Chapter 9. Europe Scleroderma Therapeutics Market Analysis and Forecast
9.1. Key Findings
9.2. Introduction
9.3. Market Size (US$ Mn) Forecast, by Indication
        9.3.1. Localized
        9.3.2. Systemic
9.4. Market Size (US$ Mn) Forecast, by Drug Class
        9.4.1. Corticosteroids
        9.4.2. Immunosuppressive Agents
        9.4.3. Endothelin receptor antagonists 
        9.4.4. Calcium Channel Blockers
        9.4.5. PDE-5 Inhibitors
        9.4.6. Chelating Agents
        9.4.7. Prostacyclin analogues
        9.4.8. Others 
9.5. Market Size (US$ Mn) Forecast, by Country
        9.5.1. U.K.
        9.5.2. Germany
        9.5.3. France
        9.5.4. Rest of Europe
9.6. Market Attractiveness Analysis, by Indication 2015 
9.7. Market Attractiveness Analysis, by Drug Class, 2015
9.8. Key Trends

Chapter 10. Asia Pacific Scleroderma Therapeutics Market Analysis and Forecast
10.1. Key Findings
10.2. Introduction
10.3. Market Size (US$ Mn) Forecast, by Indication
        10.3.1. Localized
        10.3.2. Systemic
10.4. Market Size (US$ Mn) Forecast, by Drug Class
        10.4.1. Corticosteroids
        10.4.2. Immunosuppressive Agents
        10.4.3. Endothelin receptor antagonists 
        10.4.4. Calcium Channel Blockers
        10.4.5. PDE-5 Inhibitors
        10.4.6. Chelating Agents
        10.4.7. Prostacyclin analogues
        10.4.8. Others 
10.5. Market Size (US$ Mn) Forecast, by Country
        10.5.1. China
        10.5.2. India
        10.5.3. Japan
        10.5.4. Rest of Asia Pacific
10.6. Market Attractiveness Analysis, by Indication, 2015 
10.7. Market Attractiveness Analysis, by Drug Class, 2015
10.8. Key Trends

Chapter 11. Latin America Scleroderma Therapeutics Market Analysis and Forecast
11.1. Key Findings
11.2. Introduction
11.3. Market Size (US$ Mn) Forecast, by Product 
        11.3.1. Localized
        11.3.2. Systemic
11.4. Market Size (US$ Mn) Forecast, by Distribution Channel
        11.4.1. Corticosteroids
        11.4.2. Immunosuppressive Agents
        11.4.3. Endothelin receptor antagonists 
        11.4.4. Calcium Channel Blockers
        11.4.5. PDE-5 Inhibitors
        11.4.6. Chelating Agents
        11.4.7. Prostacyclin analogues
        11.4.8. Others 
11.5. Market Size (US$ Mn) Forecast, by Country
        11.5.1. Brazil
        11.5.2. Mexico
        11.5.3. Rest of Latin America
11.6. Market Attractiveness Analysis, by Indication, 2015 
11.7. Market Attractiveness Analysis, by Drug Class, 2015
11.8. Key Trends

Chapter 12. Middle East & Africa Radiodermatitis Market Analysis and Forecast
12.1. Key Findings
12.2. Introduction
12.3. Market Size (US$ Mn) Forecast, by Indication 
        12.3.1. Localized
        12.3.2. Systemic
12.4. Market Size (US$ Mn) Forecast, by Drug Class
                12.4.1. Corticosteroids
        2.4.2. Immunosuppressive Agents
        12.4.3. Endothelin receptor antagonists 
        12.4.4. Calcium Channel Blockers
        12.4.5. PDE-5 Inhibitors
        12.4.6. Chelating Agents
        12.4.7. Prostacyclin analogues
        12.4.8. Others 
12.5. Market Size (US$ Mn) Forecast, by Country
        12.5.1. UAE
        12.5.2. South Africa
        12.5.3. Rest of Middle East & Africa
12.6. Market Attractiveness Analysis, by Indication, 2015 
12.7. Market Attractiveness Analysis, by Drug Class, 2015
12.8. Key Trends

Chapter 13. Competition Landscape
13.1. Competition Matrix
13.2. Company Profiles
        13.2.1. Actelion Pharmaceuticals, Inc. 
                  13.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.1.2. Financial Overview
                  13.2.1.3. Product Portfolio
                  13.2.1.4. SWOT Analysis
                  13.2.1.5. Strategic Overview
        13.2.2. Bayer AG
                  13.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
                  13.2.2.2. Financial Overview
                  13.2.2.3. Product Portfolio
                  13.2.2.4. SWOT Analysis
                  13.2.2.5. Strategic Overview
        13.2.3. Boehringer Ingelheim
                  13.2.3.1. Company Overview (HQ, business segments, employee strength)
                  13.2.3.2. Product Portfolio
                  13.2.3.3. SWOT Analysis
                  13.2.3.4. Financial Overview
                  13.2.3.5. Strategic Overview
        13.2.4. Corbus Pharmaceutical Holdings, Inc. 
                  13.2.4.1. Company Overview (HQ, business segments, employee strength)
                  13.2.4.2. Product Portfolio
                  13.2.4.3. SWOT Analysis
                  13.2.4.4. Strategic Overview
                  13.2.4.5. Key Developments
        13.2.5. Cumberland Pharmaceuticals Inc.
                  13.2.5.1. Company Overview (HQ, business segments, employee strength)
                  13.2.5.2. Financial Overview
                  13.2.5.3. Product Portfolio
                  13.2.5.4. SWOT Analysis
                  13.2.5.5. Strategic Overview
        13.2.6. Cytori Therapeutics, Inc.
                  13.2.6.1. Company Overview (HQ, business segments, employee strength)
                  13.2.6.2. Product Portfolio
                  13.2.6.3. SWOT Analysis
                  13.2.6.4. Financial Overview
                  13.2.6.5. Strategic Overview
        13.2.7. F. Hoffmann La Roche Ltd. 
                  13.2.7.1. Company Overview (HQ, business segments, employee strength)
                  13.2.7.2. Financial Overview
                  13.2.7.3. Product Portfolio
                  13.2.7.4. SWOT Analysis
                  13.2.7.5. Strategic Overview
        13.2.8. Gilead Sciences, Inc. 
                  13.2.8.1. Company Overview (HQ, business segments, employee strength)
                  13.2.8.2. Financial Overview
                  13.2.8.3. Product Portfolio
                  13.2.8.4. SWOT Analysis
                  13.2.8.5. Strategic Overview
        13.2.9. Merck KGaA
                  13.2.9.1. Company Overview (HQ, business segments, employee strength)
                  13.2.9.2. Product Portfolio
                  13.2.9.3. Financial Overview
                  13.2.9.4.  SWOT Analysis
                  13.2.9.5. Strategic Overview
        13.2.10. Pfizer, Inc.
                  13.2.10.1. Company Overview (HQ, business segments, employee strength)
                  13.2.10.2. Product Portfolio
                  13.2.10.3. Financial Overview
                  13.2.10.4. SWOT Analysis
                  13.2.10.5. Strategic Overview
        13.2.11. Sanofi
                  13.2.11.1. Company Overview (HQ, business segments, employee strength)
                  13.2.11.2. Product Portfolio
                  13.2.11.3. Financial Overview
                  13.2.11.4. SWOT Analysis
                  13.2.11.5. Strategic Overview

List of Tables

Table 1: Overview of active clinical trials for scleroderma
Table 2: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 3: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 4: Global Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 5: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 6: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 7: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 8: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 9: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024s
Table 10: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 11: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 12: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 13: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 14: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 15: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 16: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 17: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Indication, 2016–2024
Table 18: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Drug Class, 2016–2024
Table 19: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, by Country, 2016–2024
Table 20: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Region, 2016–2024
Table 21: Global Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 22: North America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 23: Europe Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 24: Asia Pacific Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 25: Latin America Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024
Table 26: Middle East & Africa Scleroderma Diagnostics Market Size (US$ Mn) Forecast, by Test Type, 2016–2024

List of Figures

Figure 1: Global Scleroderma Therapeutics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 2: Global Scleroderma Diagnostics Market Size (US$ Mn) and Forecast, 2016–2024
Figure 3: Scleroderma Therapeutics Market Value Share by Drug Class (2016)
Figure 4: Scleroderma Therapeutics Market Value Share by Indication (2016)
Figure 5: Scleroderma Therapeutics Market Value Share by Region (2016)
Figure 6: Scleroderma Diagnostics Market Value Share by Test Type (2016)
Figure 7: Global Scleroderma Therapeutics Market Value Share Analysis, by Indication Type, 2016 and 2024
Figure 8: Global Localized Scleroderma Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 9: Global Systemic Scleroderma Market Revenue US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 10: Scleroderma Therapeutics Market Attractiveness Analysis, by Indication Type, 2015
Figure 11: Global Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 12: Global Corticosteroids Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 13: Global Immunosuppressive Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 14: Global Endothelin Receptor Agonists Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 15: Global Calcium Channel Blockers Market Revenue ((US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 16: Global PDE-5 Inhibitors Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 17: Global Chelating Agents Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 18: Global Prostacyclin Analogs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 19: Global Other Scleroderma Drugs Market Revenue (US$ Mn) and Y-O-Y growth (%), 2014–2024 
Figure 20: Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 21: Global Scleroderma Therapeutics Market Value Share Analysis, by Region, 2016 and 2024
Figure 22: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015
Figure 23: North America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 24: North America Scleroderma Therapeutics Market Size and Y-o-Y Growth Projections, 2015–2024
Figure 25: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Country, 2015
Figure 26: North America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 27: North America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 26: highlights the estimated and forecast market value share of the drug class segments for 2016 and 2014
Figure 28: North America Scleroderma Therapeutics Market Value Share Analysis, by Country, 2016 and 2024
Figure 29: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 30: North America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 31: Europe Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 32: Europe Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 33: Europe Market Attractiveness Analysis, by Country, 2015
Figure 34: Europe Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 35: Europe Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: Europe Market Value Share Analysis, by Country, 2016 and 2024
Figure 37: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 38: Europe Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 39: Asia Pacific Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 40: Asia Pacific Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 41: Asia Pacific Market Attractiveness Analysis, by Country, 2015
Figure 42: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 43: Asia Pacific Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 44: Asia Pacific Market Value Share Analysis, by Country, 2016 and 2024
Figure 45: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 46: Asia Pacific Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 47: Latin America Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 48: Latin America Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 49: Latin America Market Attractiveness Analysis, by Country, 2015
Figure 50: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 51: Latin America Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 52: Latin America Market Value Share Analysis, by Country, 2016 and 2024
Figure 53: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 54: Latin America Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 55: Middle East & Africa Scleroderma Therapeutics Market Size (US$ Mn) Forecast, 2014–2024
Figure 56: Middle East & Africa Scleroderma Therapeutics Market Size Y-o-Y Growth Projections, 2015–2024
Figure 57: Middle East & Africa Market Attractiveness Analysis, by Country, 2015
Figure 58: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Indication, 2016 and 2024
Figure 59: Middle East & Africa Scleroderma Therapeutics Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 60: Middle East & Africa Market Value Share Analysis, by Country, 2016 and 2024
Figure 61: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Indication, 2015
Figure 62: Middle East & Africa Scleroderma Therapeutics Market Attractiveness Analysis, by Drug Class, 2015
Figure 63: Global Skin Biopsy Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 64: Global Imaging Techniques Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 65: Global Prostacyclin Analogues Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 66: Global Electrocardiogram & Echocardiogram Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024
Figure 67: Global Pulmonary Function Tests Market Revenue (US$ Mn) & Y-o-Y Growth (%), 2014–2024 
Figure 68: Global Scleroderma Diagnostics Market Attractiveness Analysis, by Test Type, 2015
Figure 69: Global Scleroderma Therapeutics Market Attractiveness Analysis, by Region, 2015

.